Hillary Clinton's medical condition may be result of her taking dangerous drug Levaquin, according to Larry Klayman

Thursday, September 15, 2016 Drug News
Email Print This Page Comment bookmark
Font : A-A+

Klayman and Victims Have Suit Pending Against Former FDA Commissioner Hamburg, Renaissance Technologies and Maker Johnson & Johnson For Racketeering and Huge Damages. Ironically Hillary Clinton Had Hamburg Appointed FDA Commissioner and She Suppressed Warnings About Severe Dangers of Levaquin!

WASHINGTON, Sept. 15, 2016 /PRNewswire/ -- It was announced yesterday that Hillary Clinton,

presidential candidate, is taking ten days of the antibiotic, Levaquin, to treat a mild case of pneumonia. http://www.usatoday.com/story/news/politics/elections/2016/09/14/hillary-clinton-campaign-medical-records/90369052/

This is deeply concerning given that July 26, 2016, the FDA announced that "Fluoroquinolones, including Levaquin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together, including: Tendinitis and tendon rupture, Peripheral neuropathy, Central nervous system effects." (FDA website, http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020634s067,020635s073,021721s034lbl.pdf)

Under the heading "Central Nervous System Effects" on the Levaquin label, it states: "Fluoroquinolones, including Levaquin, have been associated with an increased risk of central nervous system (CNS) effects, including convulsions, toxic psychoses, increased intracranial pressure…. Fluoroquinolones may also cause… tremors, restlessness, anxiety, lightheadedness, confusion, hallucinations, paranoia, depression, nightmares, insomnia, and, rarely, suicidal thoughts or acts. These reactions may occur following the first dose…."

Furthermore, the Levaquin label states, "These reactions can occur within hours to weeks after starting Levaquin. Patients of any age or without pre-existing risk factors have experienced these adverse reactions."

January 2016, Larry Klayman, attorney for five Plaintiffs damaged by Levaquin, filed a lawsuit against former FDA Commissioner Dr. Margaret Hamburg; her husband, Peter Brown, and Robert Mercer, Co-CEOs of Renaissance Technologies; James Simons, Renaissance Technologies Chair; and Johnson & Johnson (J&J), the maker of Levaquin. While Dr. Hamburg was FDA Commissioner, Renaissance Technologies hedge fund held as much as half a billion dollars in J&J stock. (Case No. 1:16-cv-00086, U.S. District Court for the District of Columbia)

Because Renaissance Technologies held as much as $3 billion in drug company stocks, this lawsuit claims that Dr. Hamburg and her husband violated the conflict of interest statute that "bars a Federal employee from participating personally and substantially… in any particular matter in which the employee has a financial interest. These restrictions also apply regarding the interests of an employee's spouse.…" (FDA website)

An estimated 5,000 people died and an estimated 80,000 people were damaged after consuming Levaquin without adequate safety warnings while Dr. Hamburg was FDA Commissioner and her husband was Renaissance Technologies Co-CEO.

It wasn't until after Dr. Hamburg left the FDA that the warnings of disabling and potentially irreversible serious adverse reactions, described above, were added to Levaquin.

Klayman questions, "Although the warnings are now on the Levaquin label, why would Clinton's physician prescribe these dangerous antibiotics to a presidential candidate? Why would a physician subject a presidential candidate to an antibiotic that could result in permanent neurological or psychiatric issues?"

For more information, contact daj142182@gmail.com or (424) 274 2579.

Media contact: Adrienne Mazzone 561-750-9800 x2270; amazzone@transmediagroup.com.  

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/hillary-clintons-medical-condition-may-be-result-of-her-taking-dangerous-drug-levaquin-according-to-larry-klayman-300328917.html

SOURCE Larry Klayman

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store